Company news
Design Therapeutics, Inc. (NASDAQ:DSGN) news
Design Therapeutics, Inc. news releases on 6ix. Latest, Sep 2, 2026: Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Press releases & updates
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
September 2, 2026
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
August 3, 2026
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
June 30, 2026
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
May 28, 2026
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
May 18, 2026
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
May 17, 2026
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
April 28, 2026
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
March 8, 2026
Design Therapeutics to Participate in Upcoming Investor Conferences
November 26, 2025
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
November 5, 2025
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
August 27, 2025
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
August 7, 2025
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
June 4, 2025
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
May 28, 2025
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
May 13, 2025
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
May 7, 2025
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
May 1, 2025
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
April 21, 2025
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
April 17, 2025
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
March 3, 2025
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
November 12, 2024
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
November 6, 2024
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 9, 2024
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
August 4, 2024
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 7, 2024
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 6, 2024
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 18, 2024
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
March 11, 2024
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
November 12, 2023
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 13, 2023
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 13, 2023
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
May 8, 2023
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
April 23, 2023
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 7, 2023
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
December 6, 2022
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
November 2, 2022
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
October 16, 2022
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
September 21, 2022
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
August 7, 2022
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
August 2, 2022
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
May 31, 2022
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
May 8, 2022
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia
March 29, 2022
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 9, 2022
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
March 8, 2022
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
February 27, 2022